SWK Holdings to Report Second Quarter 2020 Financial Results
SWK Holdings Corporation (Nasdaq: SWKH) will host a conference call on August 17, 2020, at 10:00 a.m. ET, to discuss its second quarter 2020 financial results. Interested parties can join the call by dialing (844) 378-6488 (U.S.) or (412) 317-1079 (international). An audio webcast will be available on their website, with an archive accessible for 90 days following the event. SWK specializes in providing flexible financing solutions in the healthcare sector, enhancing partnership opportunities for product marketers and royalty holders.
- SWK Holdings is focused on the growing life science sector, offering financing solutions that minimize equity dilution.
- The potential growth from Enteris Biopharma's Peptelligence® technology may enhance SWK's long-term value.
- None.
DALLAS, Aug. 14, 2020 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020, at 10:00 a.m. ET, to discuss its corporate and financial results for the second quarter 2020.
Interested participants and investors may access the conference call by dialing either:
- (844) 378-6488 (U.S.)
- (412) 317-1079 (international)
An audio webcast will be accessible via the Investors Events & Presentations section of the SWK Holdings' website: https://swkhold.investorroom.com/events. An archive of the webcast will remain available for 90 days beginning at approximately 11:00 a.m. ET, on August 17, 2020.
About SWK Holdings:
SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK's business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. SWK also owns Enteris Biopharma, whose core Peptelligence® drug delivery technology creates oral formulations of peptide-based and BCS class II, III, and IV small molecules. With Enteris, SWK has the opportunity to grow its specialty finance business by actively building a wholly-owned portfolio of milestones and royalties through licensing activities. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.
View original content:http://www.prnewswire.com/news-releases/swk-holdings-to-report-second-quarter-2020-financial-results-301112627.html
SOURCE SWK Holdings Corporation
FAQ
When will SWK Holdings report its second quarter 2020 financial results?
How can I access the SWK Holdings conference call?
Is there a webcast for the SWK Holdings financial results?
What is the focus of SWK Holdings Corporation?
